FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:MLLT3-IZUMO3

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: MLLT3-IZUMO3
FusionPDB ID: 54291
FusionGDB2.0 ID: 54291
HgeneTgene
Gene symbol

MLLT3

IZUMO3

Gene ID

4300

100129669

Gene nameMLLT3 super elongation complex subunitIZUMO family member 3
SynonymsAF9|YEATS3C9orf134|bA20A20.1
Cytomap

9p21.3

9p21.3

Type of geneprotein-codingprotein-coding
Descriptionprotein AF-9ALL1-fused gene from chromosome 9 proteinKMT2A/MLLT3 fusionKMT2A/MLLT3 fusion proteinYEATS domain-containing protein 3myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog); translocated to, 3myeloid/lymphoid or mixed-lineage leuizumo sperm-egg fusion protein 3
Modification date2020032720200313
UniProtAcc

P42568

Main function of 5'-partner protein: FUNCTION: Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA (PubMed:20159561, PubMed:20471948, PubMed:25417107, PubMed:27105114, PubMed:27545619). Specifically recognizes and binds acylated histone H3, with a preference for histone H3 that is crotonylated (PubMed:25417107, PubMed:27105114, PubMed:27545619, PubMed:30374167, PubMed:30385749). Crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors (PubMed:25417107, PubMed:27105114, PubMed:27545619). Recognizes and binds histone H3 crotonylated at 'Lys-9' (H3K9cr), and with slightly lower affinity histone H3 crotonylated at 'Lys-18' (H3K18cr) (PubMed:27105114). Also recognizes and binds histone H3 acetylated and butyrylated at 'Lys-9' (H3K9ac and H3K9bu, respectively), but with lower affinity than crotonylated histone H3 (PubMed:25417107, PubMed:27105114, PubMed:30385749). In the SEC complex, MLLT3 is required to recruit the complex to crotonylated histones (PubMed:27105114, PubMed:27545619). Recruitment of the SEC complex to crotonylated histones promotes recruitment of DOT1L on active chromatin to deposit histone H3 'Lys-79' methylation (H3K79me) (PubMed:25417107). Plays a key role in hematopoietic stem cell (HSC) maintenance by preserving, rather than confering, HSC stemness (PubMed:31776511). Acts by binding to the transcription start site of active genes in HSCs and sustaining level of H3K79me2, probably by recruiting DOT1L (PubMed:31776511). {ECO:0000269|PubMed:20159561, ECO:0000269|PubMed:20471948, ECO:0000269|PubMed:25417107, ECO:0000269|PubMed:27105114, ECO:0000269|PubMed:27545619, ECO:0000269|PubMed:30374167, ECO:0000269|PubMed:30385749, ECO:0000269|PubMed:31776511}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000355930, ENST00000475957, 
ENST00000380338, ENST00000429426, 
ENST00000380321, 
ENST00000543880, 
ENST00000604921, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score18 X 14 X 11=27721 X 1 X 1=1
# samples 251
** MAII scorelog2(25/2772*10)=-3.47092725747513
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(1/1*10)=3.32192809488736
Fusion gene context

PubMed: MLLT3 [Title/Abstract] AND IZUMO3 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: MLLT3 [Title/Abstract] AND IZUMO3 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)MLLT3(20620653)-IZUMO3(24545059), # samples:3
Anticipated loss of major functional domain due to fusion event.MLLT3-IZUMO3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
MLLT3-IZUMO3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
MLLT3-IZUMO3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
MLLT3-IZUMO3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneMLLT3

GO:0045893

positive regulation of transcription, DNA-templated

25417107|27105114

HgeneMLLT3

GO:0090090

negative regulation of canonical Wnt signaling pathway

19591803



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr9:20620653/chr9:24545059)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across MLLT3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across IZUMO3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000380338MLLT3chr920620653-ENST00000543880IZUMO3chr924545059-1176480287898203
ENST00000380338MLLT3chr920620653-ENST00000604921IZUMO3chr924545059-895480287880197
ENST00000429426MLLT3chr920620653-ENST00000543880IZUMO3chr924545059-97828298700200
ENST00000429426MLLT3chr920620653-ENST00000604921IZUMO3chr924545059-69728298682194

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000380338ENST00000543880MLLT3chr920620653-IZUMO3chr924545059-0.0073729590.9926271
ENST00000380338ENST00000604921MLLT3chr920620653-IZUMO3chr924545059-0.0099819310.99001807
ENST00000429426ENST00000543880MLLT3chr920620653-IZUMO3chr924545059-0.0021099940.99789006
ENST00000429426ENST00000604921MLLT3chr920620653-IZUMO3chr924545059-0.0038909360.99610907

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for MLLT3-IZUMO3

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
MLLT3chr920620653IZUMO3chr92454505928261VFHLHESFPRPKRGVFIYQGKLLDVC
MLLT3chr920620653IZUMO3chr92454505948064VFHLHESFPRPKRGVFIYQGKLLDVC

Top

Potential FusionNeoAntigen Information of MLLT3-IZUMO3 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
MLLT3-IZUMO3_20620653_24545059.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:01FPRPKRGVF0.9810.8799716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:08FPRPKRGVF0.96350.8699716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:05FPRPKRGVF0.93830.5872716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:01RPKRGVFIY0.9280.6237918
MLLT3-IZUMO3chr920620653chr924545059480HLA-B15:02FPRPKRGVF0.91550.9293716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:08RPKRGVFIY0.88950.6582918
MLLT3-IZUMO3chr920620653chr924545059480HLA-B15:02RPKRGVFIY0.80460.7291918
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:02FPRPKRGVF0.57640.8778716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:04FPRPKRGVF0.57640.8778716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:01FPRPKRGVFIY0.99770.6788718
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:08FPRPKRGVFIY0.99340.7298718
MLLT3-IZUMO3chr920620653chr924545059480HLA-B15:31RPKRGVFIY0.92320.564918
MLLT3-IZUMO3chr920620653chr924545059480HLA-B07:12FPRPKRGVF0.81020.6218716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B14:03FPRPKRGVF0.78630.6124716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:12FPRPKRGVF0.57640.8778716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B39:10FPRPKRGVF0.31930.6596716
MLLT3-IZUMO3chr920620653chr924545059480HLA-C12:12FPRPKRGVF0.12850.9191716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B27:14KRGVFIYQGK0.99890.8731121
MLLT3-IZUMO3chr920620653chr924545059480HLA-B07:12SFPRPKRGVF0.78760.6176616
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:77FPRPKRGVF0.9810.8799716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:23FPRPKRGVF0.9810.7889716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:24FPRPKRGVF0.94550.8702716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:17FPRPKRGVF0.94250.7515716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:30FPRPKRGVF0.94250.7515716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:77RPKRGVFIY0.9280.6237918
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:23RPKRGVFIY0.92560.6148918
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:11FPRPKRGVF0.9140.8943716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:20RPKRGVFIY0.91050.7229918
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:11RPKRGVFIY0.82620.6523918
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:24RPKRGVFIY0.77990.6591918
MLLT3-IZUMO3chr920620653chr924545059480HLA-C03:67FPRPKRGVF0.65890.8739716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:09FPRPKRGVF0.57640.8778716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B67:01FPRPKRGVF0.4220.5495716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B15:11RPKRGVFIY0.29530.5218918
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:43FPRPKRGVF0.29050.8821716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B15:08RPKRGVFIY0.28980.5369918
MLLT3-IZUMO3chr920620653chr924545059480HLA-B18:07FPRPKRGVF0.28860.8173716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B15:08FPRPKRGVF0.27150.8778716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:43RPKRGVFIY0.24860.5427918
MLLT3-IZUMO3chr920620653chr924545059480HLA-B15:11FPRPKRGVF0.24460.8689716
MLLT3-IZUMO3chr920620653chr924545059480HLA-B18:04RPKRGVFIY0.24120.6312918
MLLT3-IZUMO3chr920620653chr924545059480HLA-B18:07RPKRGVFIY0.07910.5519918
MLLT3-IZUMO3chr920620653chr924545059480HLA-C14:02SFPRPKRGVF0.90980.9526616
MLLT3-IZUMO3chr920620653chr924545059480HLA-C14:03SFPRPKRGVF0.90980.9526616
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:23FPRPKRGVFIY0.99770.6689718
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:77FPRPKRGVFIY0.99770.6788718
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:17FPRPKRGVFIY0.99380.5024718
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:30FPRPKRGVFIY0.99380.5024718
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:24FPRPKRGVFIY0.98880.7091718
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:11FPRPKRGVFIY0.98420.7151718
MLLT3-IZUMO3chr920620653chr924545059480HLA-B15:11FPRPKRGVFIY0.96280.5964718
MLLT3-IZUMO3chr920620653chr924545059480HLA-B15:08FPRPKRGVFIY0.9610.617718
MLLT3-IZUMO3chr920620653chr924545059480HLA-B35:43FPRPKRGVFIY0.95920.6228718
MLLT3-IZUMO3chr920620653chr924545059480HLA-B18:07FPRPKRGVFIY0.82010.6696718

Top

Potential FusionNeoAntigen Information of MLLT3-IZUMO3 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
MLLT3-IZUMO3_20620653_24545059.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0801PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0803PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0803KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0805PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0805KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0808PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0811PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0814PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0814KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0816PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0818PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0818KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0823PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0823KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0826PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0827PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0827KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0829PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0829KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0833PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0833KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0835PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0835KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0836PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0836KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0837PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0837KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0838PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0838KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0839PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0840PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-0840KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1303PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1303KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-13101PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1310PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1312PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1312KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1313PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1313KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1321PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1321KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1330PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1330KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1333PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1333KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1338PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1349PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1349KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1355PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1365PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1366PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1366KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1388PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1390PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1390KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1395PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1395KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1413PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1422PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1422KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1425PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1425KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1453PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1453KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1463PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1463KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1469PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1469KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1485PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1501PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1501RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1501KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1502PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1502RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1502KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1503PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1503RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1504PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1504RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1504KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1505PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1505RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1505KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1506PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1506RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1506KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1507PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1507RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1507KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1508PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1508RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1508KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1509PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1509RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1509KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1510PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1510RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1510KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1511PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1511RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1512PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1512RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1512KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1513PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1513RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1513KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1514PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1514RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1514KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1515PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1515RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1516PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1516RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1516KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1518PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1518RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1518KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1519PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1519RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1519KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1520PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1520RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1520KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1521PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1521RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1521KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1522PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1522RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1522KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1523PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1523RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1524PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1524RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1524KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1526PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1526RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1526KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1527PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1528PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1528RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1528KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1529PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1529RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1530PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1530RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1530KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1531PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1531RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1531KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1532PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1532RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1532KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1533PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1533RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1533KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1535PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1535RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1535KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1536PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1536RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1536KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1537PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1537RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1537KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1538PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1538RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1538KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1539PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1539RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1539KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1540PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1540RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1540KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1541PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1541RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1541KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1542PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1542RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1542KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1543PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1543RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1543KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1544PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1544RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1544KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1545PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1545RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1545KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1546PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1546RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1546KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1547PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1547RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1547KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1548PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1548RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1548KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1549PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1549RPKRGVFIYQGKLLD924
MLLT3-IZUMO3chr920620653chr924545059480DRB1-1549KRGVFIYQGKLLDVC1126
MLLT3-IZUMO3chr920620653chr924545059480DRB5-0202PKRGVFIYQGKLLDV1025
MLLT3-IZUMO3chr920620653chr924545059480DRB5-0204PKRGVFIYQGKLLDV1025

Top

Fusion breakpoint peptide structures of MLLT3-IZUMO3

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
8559SFPRPKRGVFIYQGMLLT3IZUMO3chr920620653chr924545059480

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of MLLT3-IZUMO3

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN8559SFPRPKRGVFIYQG-7.9962-8.1096
HLA-B14:023BVN8559SFPRPKRGVFIYQG-5.70842-6.74372
HLA-B52:013W398559SFPRPKRGVFIYQG-6.83737-6.95077
HLA-B52:013W398559SFPRPKRGVFIYQG-4.4836-5.5189
HLA-A11:014UQ28559SFPRPKRGVFIYQG-10.0067-10.1201
HLA-A11:014UQ28559SFPRPKRGVFIYQG-9.03915-10.0745
HLA-A24:025HGA8559SFPRPKRGVFIYQG-6.56204-6.67544
HLA-A24:025HGA8559SFPRPKRGVFIYQG-5.42271-6.45801
HLA-B44:053DX88559SFPRPKRGVFIYQG-7.85648-8.89178
HLA-B44:053DX88559SFPRPKRGVFIYQG-5.3978-5.5112
HLA-A02:016TDR8559SFPRPKRGVFIYQG-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of MLLT3-IZUMO3

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
MLLT3-IZUMO3chr920620653chr9245450591121KRGVFIYQGKAAAGAGGTGTCTTTATCTATCAAGGCAAGC
MLLT3-IZUMO3chr920620653chr924545059616SFPRPKRGVFGCTTTCCTAGGCCAAAAAGAGGTGTCTTTA
MLLT3-IZUMO3chr920620653chr924545059716FPRPKRGVFTTCCTAGGCCAAAAAGAGGTGTCTTTA
MLLT3-IZUMO3chr920620653chr924545059718FPRPKRGVFIYTTCCTAGGCCAAAAAGAGGTGTCTTTATCTATC
MLLT3-IZUMO3chr920620653chr924545059918RPKRGVFIYGGCCAAAAAGAGGTGTCTTTATCTATC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
MLLT3-IZUMO3chr920620653chr9245450591025PKRGVFIYQGKLLDVCAAAAAGAGGTGTCTTTATCTATCAAGGCAAGCTTCTCGATGTCT
MLLT3-IZUMO3chr920620653chr9245450591126KRGVFIYQGKLLDVCAAAGAGGTGTCTTTATCTATCAAGGCAAGCTTCTCGATGTCTGCC
MLLT3-IZUMO3chr920620653chr924545059924RPKRGVFIYQGKLLDGGCCAAAAAGAGGTGTCTTTATCTATCAAGGCAAGCTTCTCGATG

Top

Information of the samples that have these potential fusion neoantigens of MLLT3-IZUMO3

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
GBMMLLT3-IZUMO3chr920620653ENST00000380338chr924545059ENST00000543880TCGA-32-5222-01A

Top

Potential target of CAR-T therapy development for MLLT3-IZUMO3

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneIZUMO3chr9:20620653chr9:24545059ENST0000054388017175_1950240.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to MLLT3-IZUMO3

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to MLLT3-IZUMO3

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneMLLT3C0005586Bipolar Disorder1PSYGENET